McDermott and Bull executive Search
 

Other News

Corindus Promotes Doug Teany to Chief Operating Officer

WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it has appointed Douglas Teany, currently the company’s Senior Vice President of R&D and Operations, to Chief Operating Officer, effective immediately. Teany brought eighteen years of experience to Corindus, driving operational excellence […]

Humacyte Appoints Jeffrey Lawson MD, PhD as President and Chief Executive Officer

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Jeffrey Lawson MD, PhD has been appointed President and Chief Executive Officer. Carrie S. Cox has assumed the role of Executive Chairman. Dr. Lawson, an innovator, scientist and vascular surgeon has been involved in the […]

FEops Strengthens Management Team

GENT, Belgium–(BUSINESS WIRE)–FEops, the leader in personalized computational modeling and simulation for structural heart interventions, today announced the expansion of its management team with the appointments of Christian Vincent as Director of Therapy Development and Nico Uwents as Director of Business Development. “Both Christian and Nico have a long track record of success in […]

IPS HEART, Resident of Johnson & Johnson Innovation, Uses Human Stem Cells for the First Time to Actually Reverse Heart Attack Damage

HOUSTON–(BUSINESS WIRE)–IPS HEART, resident of Johnson & Johnson Innovation, JLABS is pioneering the use of IPS cellular therapy for the replacement of heart tissue after heart attack, heart failure and duchenne cardiomyopathy. Recent results were presented at the 82nd Annual Scientific Meeting of the Japanese Circulation Society showing over 66% […]

Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina

BASKING RIDGE, N.J., June 19, 2018 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases, announces today that the U.S. Food and Drug Administration (“FDA”) has granted regenerative medicine advanced therapy (“RMAT”) designation to […]

Zenosense, Inc.: Breakthrough Quantitative MIDS Testing Results

VALENCIA, SPAIN., June 19, 2018 (GLOBE NEWSWIRE) — Zenosense, Inc. (OTC PINK: ZENO) (“Zenosense”, the “Company”), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of Care, is pleased to announce that its […]

Silk Road Medical Announces Key Events for Society for Vascular Surgery 2018 Vascular Annual Meeting

SUNNYVALE, Calif.–(BUSINESS WIRE)–Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, today announced key events at the upcoming Society for Vascular Surgery 2018 Vascular Annual Meeting (VAM) June 20-23 at the Hynes Convention Center in Boston. These include real-world data presentations comparing […]

BioTrace Medical Announces Key Events Featuring Tempo® Lead at TVT 2018

MENLO PARK, Calif.–(BUSINESS WIRE)–BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the Transcatheter Valve Therapies (TVT) structural heart disease summit, which will take place June 20-22 at the Sheraton Grand Chicago. The company’s Tempo® Temporary Pacing Lead will be featured in a […]

Caelum Biosciences Announces Presentation of Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis at American Society of Echocardiography 29th Annual Scientific Sessions

NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) — Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company developing treatments for rare and life-threatening diseases, today announced that Columbia University (“Columbia”) will present a complete analysis of cardiac data from the Phase 1b trial of CAEL-101 (mAb 11-1F4) for the […]